Filters








3,579 Hits in 6.8 sec

Inter-Cohort Validation of SuStaIn Model for Alzheimer's Disease

Damiano Archetti, Alexandra L. Young, Neil P. Oxtoby, Daniel Ferreira, Gustav Mårtensson, Eric Westman, Daniel C. Alexander, Giovanni B. Frisoni, Alberto Redolfi, for Alzheimer's Disease Neuroimaging Initiative and EuroPOND Consortium
2021 Frontiers in Big Data  
This study proves the transferability of a SuStaIn model for AD from research data to less-structured clinical cohorts, and indicates transferability to the clinical setting.  ...  Subject subtyping proved to be consistent in time for all cohorts and the staging provided by the model was correlated with cognitive performance.  ...  Inter-Cohort SuStaIn Validation  ... 
doi:10.3389/fdata.2021.661110 pmid:34095821 pmcid:PMC8173213 fatcat:e4zx7jbhrvh2bcb6ycg6gat2zu

Page 2918 of Psychological Abstracts Vol. 88, Issue 8 [page]

2001 Psychological Abstracts  
(U Miami, Dept of Psychiatry & Behavioral Sci- ences, Miami Beach, FL) An evaluation of the NINCDA-ADRDA neu- ropsychological criteria for the assessment of Alzheimer’s disease: A confirmatory factor analysis  ...  Study | examined inter-subtest correlation coefficients across the 9 subtests of the WRAML and compared across 3 age cohorts (5, 11, and 16-17 yr olds).  ... 

Characterizing the spatiotemporal variability of Alzheimer's disease pathology [article]

Jacob W Vogel, Alexandra L Young, Neil P Oxtoby, Ruben Smith, Rik Ossenkoppele, Olof T Strandberg, Renaud La Joie, Leon M Aksman, Michel J Grothe, Yasser Iturria-Medina, Michael J Pontecorvo, Michael D Devous (+6 others)
2020 medRxiv   pre-print
Alzheimer's disease (AD) is characterized by the progressive spread of tau pathology throughout the cerebral cortex.  ...  We analyzed 1612 tau-PET scans and applied to this sample a disease progression modeling framework designed to identify spatiotemporal trajectories of pathological progression.  ...  Pedro Rosa-Neto, Alain Dagher, Edith Hamel and William Seeley for feedback during the composition of this manuscript. JWV acknowledges support from the government of Canada through  ... 
doi:10.1101/2020.08.20.20176883 fatcat:athma2ynxbdrfkgd6tcp2wfpdu

Multi-study validation of data-driven disease progression models to characterize evolution of biomarkers in Alzheimer's disease

Damiano Archetti, Silvia Ingala, Vikram Venkatraghavan, Viktor Wottschel, Alexandra L. Young, Maura Bellio, Esther E. Bron, Stefan Klein, Frederik Barkhof, Daniel C. Alexander, Neil P. Oxtoby, Giovanni B. Frisoni (+1 others)
2019 NeuroImage: Clinical  
The Alzheimer's Disease Neuroimaging Initiative (ADNI) data set was used as training set for the constriction of disease models while a collection of multi-centric data cohorts was used as test set for  ...  We demonstrated inter-cohort transferability of two disease progression models and their robustness in detecting AD phases.  ...  Conclusions We have performed an inter-cohort model transferability study and model performance comparison via external validation approach for event-based models.  ... 
doi:10.1016/j.nicl.2019.101954 pmid:31362149 pmcid:PMC6675943 fatcat:f5fcom2wjja47jdhwcqbwdtjs4

Deep learning assisted quantitative assessment of histopathological markers of Alzheimer's disease and cerebral amyloid angiopathy

Valentina Perosa, Ashley A. Scherlek, Mariel G. Kozberg, Lindsey Smith, Thomas Westerling-Bui, Corinne A. Auger, Serge Vasylechko, Steven M. Greenberg, Susanne J. van Veluw
2021 Acta Neuropathologica Communications  
To overcome these issues, we have developed six deep learning-based models, that identify some of the most characteristic markers of Alzheimer's disease (AD) and cerebral amyloid angiopathy (CAA).  ...  Validation of all models indicated a very good to excellent performance compared to three independent expert human raters.  ...  Alzheimer's tissue samples were obtained from the South West  ... 
doi:10.1186/s40478-021-01235-1 pmid:34419154 pmcid:PMC8380352 fatcat:2jpdfpmyxbfrdmmkvstig4tb6i

Donanemab (LY3002813) dose-escalation study in Alzheimer's disease

Stephen Loucian Lowe, Brian A Willis, Anne Hawdon, Fanni Natanegara, Laiyi Chua, Joanne Foster, Sergey Shcherbinin, Paul Ardayfio, John R Sims
2021 Alzheimer s & Dementia Translational Research & Clinical Interventions  
This study explored the safety and tolerability features of donanemab (LY3002813) in patients with mild cognitive impairment due to Alzheimer's disease (AD) or mild to moderate AD dementia.  ...  once per month for up to four doses depending on the initial doses (only cohort 1 went from 0.1 mg/kg to a higher dose of 0.3 mg/kg during the MAD phase).  ...  Alzheimer's disease (AD).  ... 
doi:10.1002/trc2.12112 pmid:33614890 pmcid:PMC7882532 fatcat:3cgg7u27tfg2fpzsw2vpksrvay

Developing a national strategy to prevent dementia: Leon Thal Symposium 2009

Zaven S. Khachaturian, Deborah Barnes, Richard Einstein, Sterling Johnson, Virginia Lee, Allen Roses, Mark A. Sager, William R. Shankle, Peter J. Snyder, Ronald C. Petersen, Gerard Schellenberg, John Trojanowski (+24 others)
2010 Alzheimer's & Dementia  
Among the major impediments to the design of clinical trials for the prevention of Alzheimer's disease (AD), the most critical is the lack of validated biomarkers, assessment tools, and algorithms that  ...  The deliberations of LTS'09 included presentations and reviews of different approaches (algorithms, biomarkers, or measures) for identifying asymptomatic individuals at elevated risk for AD who would be  ...  LeeAnn Mandarino deserves special mention of appreciation for helping to coordinate this event, along with all of the participants who bestow their knowledge and talents toward the goal of the prevention  ... 
doi:10.1016/j.jalz.2010.01.008 pmid:20298968 pmcid:PMC4298995 fatcat:tuk7ic6f5jfzzmq5fttazqq4gy

ABO Blood Group and Dementia Risk – A Scandinavian Record-Linkage Study

Senthil K Vasan, Klaus Rostgaard, Henrik Ullum, Mads Melbye, Henrik Hjalgrim, Gustaf Edgren, Masaki Mogi
2015 PLoS ONE  
Overall, our study showed no association between ABO blood group and risk of Alzheimer's disease, vascular dementia or unspecified dementia.  ...  Results Among 1,598,294 donors followed over 24 million person-years of observation we ascertained 3,615 cases of Alzheimer's disease, 1,842 cases of vascular dementia, and 9,091 cases of unspecified dementia  ...  Acknowledgments We are greatly indebted to all the blood banks in Sweden and Denmark for both collecting and contributing data to this study. Author Contributions  ... 
doi:10.1371/journal.pone.0129115 pmid:26042891 pmcid:PMC4456384 fatcat:anjjdzqofvcmxogehdfjcjk4ue

Neuroimaging-based Individualized Prediction of Cognition and Behavior for Mental Disorders and Health: Methods and Promises [article]

JING SUI, Rongtao Jiang, Juan Bustillo, Vince D. Calhoun
2020 bioRxiv   pre-print
Finally, we highlight a few challenges related to combining multimodal data, longitudinal prediction, external validations and the employment of deep learning methods that have emerged from our review  ...  Regression-based multivariate models (hereafter "predictive modeling") provide a powerful and widely-used approach to predict human behavior with neuroimaging features.  ...  Acknowledgments This work is supported in part by the National Institute of Health (1R01MH117107, R01EB020407, The authors declare no biomedical financial interests or potential conflicts of interest.  ... 
doi:10.1101/2020.02.22.961136 fatcat:rtxaa5cjnvekzhkwcokmmf2toe

2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease

Keith N. Fargo, Paul Aisen, Marilyn Albert, Rhoda Au, Maria M. Corrada, Steven DeKosky, David Drachman, Howard Fillit, Laura Gitlin, Magali Haas, Karl Herrup, Claudia Kawas (+28 others)
2014 Alzheimer's & Dementia  
treating Alzheimer's disease by 2025.  ...  Pursuant to this, the US Department of Health and Human Services (HHS) released the National Plan to Address Alzheimer's Disease in 2012, including an ambitious research goal of preventing and effectively  ...  validate disease targets for Alzheimer's and other diseases [51] .  ... 
doi:10.1016/j.jalz.2014.08.103 pmid:25341459 fatcat:vjpraopvtvhw7lisdmpdjgtrnq

Plasma neuregulin 1 as a synaptic biomarker in Alzheimer's disease: a discovery cohort study

Agathe Vrillon, François Mouton-Liger, Matthieu Martinet, Emmanuel Cognat, Claire Hourregue, Julien Dumurgier, Elodie Bouaziz-Amar, Ann Brinkmalm, Kaj Blennow, Henrik Zetterberg, Jacques Hugon, Claire Paquet
2022 Alzheimer's Research & Therapy  
Background Synaptic dysfunction is an early core feature of Alzheimer's disease (AD), closely associated with cognitive symptoms.  ...  CSF synaptic markers were measured using ELISA for GAP-43 and neurogranin and through immunoprecipitation mass spectrometry for SNAP-25.  ...  Introduction Synaptic impairment is a core feature of Alzheimer's disease (AD) and one of the earliest detectable changes [1, 2] .  ... 
doi:10.1186/s13195-022-01014-7 pmid:35606871 pmcid:PMC9125890 fatcat:3w4kordsmfdfdiefqu7dmgwt6u

Rationale and Structure for a New Center for Studies on Prevention of Alzheimer's Disease (StoP-AD)

J C S Breitner, J Poirier, P E Etienne, J M Leoutsakos
2016 The journal of prevention of Alzheimer's disease  
We describe events spanning over 20 years that have shaped our approach to identification of interventions that may delay symptoms in Alzheimer's disease (AD).  ...  These events motivated the development of a new Centre for Studies on Prevention of AD that includes an observational cohort of cognitively normal high-risk persons and INTREPAD, a nested two-year randomized  ...  We are deeply grateful for the tireless generosity and commitment of the participants in our work, and for helpful comments and the personal commitment of Prof. Alan Evans and Mr.  ... 
doi:10.14283/jpad.2016.121 pmid:29199324 fatcat:2nc534lkdzar7lnaftkihxgxmm

Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid

Johan Gobom, Lucilla Parnetti, Pedro Rosa-Neto, Martin Vyhnalek, Serge Gauthier, Samuela Cataldi, Ondrej Lerch, Jan Laczo, Katerina Cechova, Marcus Clarin, Andrea I. Benet, Tharick A. Pascoal (+17 others)
2021 Clinical Chemistry and Laboratory Medicine  
For the Aβ 1-42/Aβ 1-40 ratio, the cutpoint was determined by mixture model analysis of 2,782 CSF samples.  ...  Clinical cutpoints for Aβ 1-42, tTau, and pTau was determined by analysis of three cohorts of clinically diagnosed patients, comprising 651 CSF samples.  ...  Introduction Alzheimer's disease (AD) is the most common cause of dementia [1] .  ... 
doi:10.1515/cclm-2021-0651 pmid:34773730 fatcat:vd3e3j765zdsbiasb2nyalg6ki

Multivariate classification of patients with Alzheimer's and dementia with Lewy bodies using high-dimensional cortical thickness measurements: an MRI surface-based morphometric study

Alexander V. Lebedev, E. Westman, M. K. Beyer, M. G. Kramberger, C. Aguilar, Z. Pirtosek, D. Aarsland
2012 Journal of Neurology  
The project has been conducted at the Centre for age-related medicine (Regionalt kompetansesenter for eldremedisin og samhandling, SESAM) at the Stavanger University hospital (SUS) under the supervision  ...  Random Forest ensembles for detection and prediction of Alzheimer's Disease with a good between-cohort robustness (Submitted); 3.  ...  Reliability assessment In order to check intra-and inter-scanner reliability in the DemWest cohort, we performed a validation study using human phantom scanning.  ... 
doi:10.1007/s00415-012-6768-z pmid:23224109 fatcat:ynen6532azf2th6tqvh647glku

A Critical Proton MR Spectroscopy Marker of Alzheimer's Disease Early Neurodegenerative Change: Low Hippocampal NAA/Cr Ratio Impacts APOE ɛ4 Mexico City Children and Their Parents

Lilian Calderón-Garcidueñas, Antonieta Mora-Tiscareño, Gastón Melo-Sánchez, Joel Rodríguez-Díaz, Ricardo Torres-Jardón, Martin Styner, Partha S. Mukherjee, Weili Lin, Valerie Jewells
2015 Journal of Alzheimer's Disease  
This is an author-produced, peer-reviewed version of this article. The final, definitive version of this document can be found online at Journal of Alzheimer's Disease, published by IOS Press.  ...  This is an author-produced, peer-reviewed version of this article. The final, definitive version of this document can be found online at Journal of Alzheimer's Disease, published by IOS Press.  ...  Acknowledgments We thank all children and their parents for their participation in this study. Grant Support None References  ... 
doi:10.3233/jad-150415 pmid:26402110 fatcat:2ydyptsgsveedippbvg2ini34y
« Previous Showing results 1 — 15 out of 3,579 results